

SUPPLEMENTARY INFORMATION

Targeted suppression of microRNA-33 in lesional macrophages using pH low-insertion peptides (pHLIP) improves atherosclerotic plaque regression

Xinbo Zhang, Noemi Rotllan, Alberto Canfrán-Duque, Jakub Toczek, Anna Moshnikova, Shipra Malik, Nathan L. Price, Elisa Araldi, Wen Zhong, Mehran M. Sadeghi, Oleg A. Andreev, Raman Bahal, Yana Reshetnyak, Yajaira Suárez, Carlos Fernández-Hernando.

SUPPLEMENTAL FIGURE LEGENDS

Supp Figure 1. pH low inducible peptides (pHLIP) promotes delivery of miR-33 inhibitors to the atherosclerotic plaques. **a-b**, Representative images (**a**) and quantification (**b**) of tissues from low density lipoprotein receptor knockout (*Ldlr*^{-/-}) mice injected with fluorescently labeled targeted (A750-Var3) or non-inserting control (A750-5K-Var3) constructs. *Ldlr*^{-/-} mice were fed a western diet (WD) for 3 months to induce atherosclerosis and tissues were harvested 4-24 hours post injection of constructs. **c**, Representative images demonstrating uptake of A546-Var3 into liver and kidney with A546-5K-Var3 as control.

Supp Figure 2. Targeted silencing of miR-33 does not result in differences in circulating lipids, lipoprotein profiles and body weight. **a**, Measurement of plasma total cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides from Low density lipoprotein receptor knockout (*Ldlr*^{-/-}) mice injected anti-miR-33 peptide nucleic acid delivery vector (anti-miR33^{pHLIP}) or scrambled control (Src^{pHLIP}) (*n*= 6-13 each group). **b**, Lipoprotein profiles by FPLC from *Ldlr*^{-/-} mice injected anti-miR33^{pHLIP} or Src^{pHLIP}. **c**, Body weight of *Ldlr*^{-/-} mice injected anti-miR33^{pHLIP} or Src^{pHLIP} (*n*= 14-18 per group). Quantification represents the mean ± s.e.m. Data were analyzed by one-way ANOVA with Bonferroni correction for multiple comparisons.

Supp Figure 3. Selective targeting of miR-33 by pHLP peptides shows no difference in circulating leukocytes composition and hepatic function. **a**, Quantification of peripheral blood counts by hemocytometer from *Ldlr*^{-/-} mice injected anti-miR-33 peptide nucleic acid delivery vector (anti-miR33^{pHLP}) or scrambled control (Src^{pHLP}) (*n*= 7-9 each group). **b**, Quantification of serum hepatotoxicity markers, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), from *Ldlr*^{-/-} mice injected anti-miR33^{pHLP} or Src^{pHLP} (*n*= 7-9 each group). Quantification represents the mean \pm s.e.m. Data were analyzed by an unpaired two-sided Student's t-test.

Supp Figure 4. Targeted silencing of miR-33 does not influence macrophage and smooth muscle cell content in atherosclerotic lesions. Low density lipoprotein receptor knockout (*Ldlr*^{-/-}) mice were placed on a western diet (WD) for 3 months, and then switched to a chow diet and received anti-miR-33 peptide nucleic acid delivery vector (anti-miR33^{pHLP}) or scrambled control (Src^{pHLP}) at a dose of 1 mg/kg body weight every week for a total of 5 injections. Representative immunofluorescence staining of macrophage (CD68 positive) and smooth muscle cell (α -smooth muscle actin) in cross sections of the aortic root from *Ldlr*^{-/-} mice injected with anti-miR33^{pHLP} or Src^{pHLP} vectors. Quantification of macrophage and smooth muscle cell content are shown in the right panel. Data were analyzed by one-way ANOVA with Bonferroni correction for multiple comparisons (*n*= 6-13 per group). Scale bar: 100 μ m.


Supp Figure 5. pHLP-mediated miR-33 silencing does not influence hepatic ABCA1 and ABCG1 expression. Representative Western blot analysis of ABCA1 and ABCG1 in the liver from mice injected with anti-miR-33^{pHLP} or Src^{pHLP}. Quantification are shown in the bottom panels. Data were analyzed by an unpaired two-sided Student's t-test (*n*= 5 per group). Quantification represents the mean \pm s.e.m.

Supp Figure 6. Single cell RNAseq analysis of whole aortic cells treated with anti-miR-33 peptide nucleic acid delivery vector (anti-miR33^{pHLIP}) or scrambled control (Src^{pHLIP}). **a**, Heatmap of the 20 most upregulated genes in each cluster defined in **Fig. 4a** and selected enriched genes used for biological identification of each cluster. **b**, Proportions of cells extracted from the atherosclerotic aortas of anti-miR33^{pHLIP} and Src^{pHLIP}-treated mice.


Supp Figure 7. Gene expression features from indicated monocytes/macrophages clusters. **a**, Uniform manifold approximation and projection (UMAP) plots of *Cd14*, *Cd68*, *Adgre1*, and *Csf1r* in sorted cells from atherosclerotic plaques of mice treated with anti-miR-33 peptide nucleic acid delivery vector (anti-miR33^{pHLIP}) or scrambled control (Src^{pHLIP}) . **b**, UMAP plots of most highly upregulated genes for clusters of Trem2^{high} Mac, F10⁺ Mono, Inflammatory Mac and Stem-like Mac. **c**, UMAP plots of most highly upregulated genes for ECM^{high} Mac cluster.

Supplementary Fig 1


a




b




c





Supplementary Figure 2





Supplemental Figure 3





Supplemental Figure 4



Supplemental Figure 5



Supplemental Figure 6



Supplemental Figure 7

